Top 5 is acquired by Healthcare Technologies since 2020.

PWC's Global Mergers and Acquisitions Industry Insights: Pharmaceuticals and Life Sciences report shows that in the first half of 2020, the number and volume of transactions in the pharmaceutical and life sciences industries around the world declined as a result of the new crown outbreak.
medical technology alone, data show that while more than $21 billion worth of mergers and acquisitions are still under way in the first half of 2020, the total value of healthcare technology transactions completed in this area is less than $2 billion.
However, in the second half of the year, although the global mergers and acquisitions market remains depressed, as the market and investment institutions gradually stabilize in the crisis, the medical technology sector mergers and acquisitions transactions may have rebounded and rebounded.
recently, Evaluate's official article "Steris turns the Key on 2020's most bigst buy" counts the amount of medical technology mergers and acquisitions since 2020 TOP 5 events, it is worth mentioning that these five major acquisitions occurred in the second half of 2020, and the total amount has exceeded $45 billion.
we briefly comb through the details of these five acquisitions.
.S. digital healthcare giant Teladoc Health announced on August 5th that it would merge with Livongo, a tele-chronic care platform, to create a virtual telemedicanic company.
terms of the agreement, the combined Teladoc and Livongo shareholders will own 58 per cent and 42 per cent, respectively.
Livongo is valued at $18.5 billion in the merger, which industry insiders estimate could be worth $38 billion, or about $270 billion.
, the huge deal is seen as an unprecedented event in the history of digital medicine.
, the largest tele-virtual healthcare company in the United States, teladoc Health was founded in 2002 and successfully landed on the NYSE Capital Markets in 2015.
the company primarily provides telemedican services on demand through telephone or video conferencing software and mobile applications, patients and doctors can conduct remote consultations to gain access to healthcare knowledge and health plans.
2020, Teladoc Health generated revenue of $241 million in the second quarter alone, up 85.01 percent year-on-year, thanks to positive incentives for telemedicme from the outbreak.
fact, if Teladoc Health's revenue in 2015 was only $770 million, it would have reached $553 million by 2019.
" expects the combined company to have about 19 times the revenue multiple by 2021.
is a high number compared to Teladoc Health's history of trading.
," said Glen Santangelo, an analyst at Guggenheim.
is not the first time Teladoc Health has made a deal, especially in recent years, when Teladoc Health has acquired a number of companies involved in the consulting business in an effort to distance it it itselves from its rivals.
the outbreak, however, has also spurred the rapid growth of Teladoc Health's rivals, and to further maintain its lead, it has acquired Livongo, another leader in digital healthcare.
, a company that uses digital technology and smart devices to provide chronic disease management counseling services, was founded in 2008 and went public in 2019.
but there are still sceptics in the industry about the acquisition, arguing that Teladoc paid too much for Livongo and that Livongo's business is not fully in synergy with Teladoc's core telemedican business.
, of course, it's more about expecting Teladoc Health to not only secure its leading position through a merger, but also provide a better story for the market by moving into the slow-motion management space.
, the merger provides further validation for digital healthcare as a whole, a view of the market's hesitation and wait-and-see attitude.
2 Siemens Medical's $16.4bn acquisition of Varian Medical Systems was announced on August 2nd that it would buy Varian Medical Systems, the US cancer medical technology maker, for $16.4bn in cash, a deal more than 20 per cent higher than Varian's market capitalisation at the time.
72-year history, as the big brother of the radiotherapy equipment market, it is the world's largest X-ray digital imaging company, linear accelerators, gamma knives and other products major manufacturers.
it is known that Valian has installed more than 8000 radiotherapy systems worldwide, accounting for more than 50% of the global market share of radiotherapy, and in the field of analytical instruments, Wallian is also well-known, has launched the world's first commodity atomic absorption spectrometer, the first FT-IR, the first 900 Hz NMR and so on.
acquisition is also a strong joint.
As one of the big three medical imaging companies, Siemens' most popular products are molecular diagnostic products and MRIs, both of which are currently mainly used for cancer diagnosis, combined with Valian to extend its business from diagnosis to treatment, forming a complete closed loop.
this means that through this acquisition, Siemens will enter the oncology radiotherapy market and form a fully integrated platform that truly covers the entire process of cancer, from diagnosis to treatment and care.
In fact, Siemens and Valian have a long history of cooperation, the two sides have been partners for more than a decade, so that the former Wallian and Siemens reached a cooperation in the United States and other agreed areas, Warian radiation customers on behalf of Siemens to sell its imaging diagnostic products, Siemens can also sell Valian radiotherapy systems to its customers.
Based on this acquisition, the ultimate goal is to provide a comprehensive portfolio of integrated oncology products that will add Valian's linear accelerators, radiosurgery equipment and proton therapy suites to Siemens' range of imaging hardware, laboratory diagnostics and hospital consulting services.
3 Illumina's $8 billion acquisition of Grail on September 21st, Illumina announced that it had reached a final agreement with Grail to acquire GRAIL for $8 billion in cash and stock, in addition to future payments to GRAIL shareholders, which account for a single-digit percentage of some GRAIL-related revenue.
this became the biggest acquisition ever made by Illumina.
founded in 1998, Illumina is now the world's largest DNA sequencing company, with a market share of 83.9 percent, far more than any of its competitors, according to Next Generation Genomics.
in the case of this acquisition, it is interesting to note that GRAIL was originally separated from Illumina and is now back in Illumina's arms after some ups and downs.
Specifically, GRAIL was founded in 2015 with support from Illumina's NGS technology to develop the latest data science and machine learning and create an atlas of cancer signals in the blood for early cancer detection testing;
, Grail has had a good time in the capital markets, raising nearly $2 billion.
help and financial support from Illumina, Grail has launched four products, including the fist product Gallei.
This is a multi-cancer early screening product, using GRAIL developed a cfDNA-targeted methylation-based blood test analysis method, can use a tube of blood for more than 50 kinds of tumor early screening products.
Compared to other early screening products already on the market and coming soon, Galleri has the advantage of high specificity and broad spectrum, while a false positive rate of less than 1 percent guarantees the reliability of the test and opens the gap with many other tumor early screening products.
Grail expects the product to be available in 2021.
that may or may be one of the factors that helped Ilumina bring Grail back into the top.
, Illumina's main source of revenue has been the sale of sequencing instruments and experimental consumables, with fewer downstream layouts in the industry.
this successful acquisition, Illumina may expand from a pure sequencing provider to downstream applications, further consolidating its dominance in DNA sequencing.
4Invitae's $1.4 billion acquisition of Archer DX on June 22, Invitae, a leader in genetic disease testing, announced that it will acquire ArcherDx, a cancer genetic testing company, to include the latter in the income sacs of gene testing and liquid biopsy technology and related products for tumor efficacy prediction and monitoring.
under the terms of the deal, Invitae acquired ArcherDx for $325 million in cash and 30 million shares.
addition, invitae will pay up to 27 million common shares to ArcherDx's existing shareholders, with a total value of about $1.4 billion, depending on the milestone.
Invitae is a leader in cancer diagnosis and genetic risk testing, and its genetic testing products are divided into diagnostic testing, risk estimation, and reproductive genetics.
ArcherDX is a company that provides gene sequencing products and services for determining the most effective cancer treatments and personalized cancer surveillance, developing solid tumor companion diagnostic products, personalized tumor recurrence monitoring products, and tumor research products.
that AncherDx products are currently used in more than 300 laboratories around the world, with more than 50 pharmaceutical companies and CRO companies.
"with ArcherDx's technology, capabilities and team support, Invitae is able to accelerate the application of gene information in the management of cancer patients throughout the course of the disease."
, according to Sean George, Chief Executive Officer of Invitae, Invitae's products will provide the most advanced information needed for personalized cancer care, from risk assessment, diagnostic detection therapy optimization, and recurrence monitoring.
5 Steris' $850 million acquisition of KeySeil on October 6th, Steris announced that it had signed a final agreement with KeySely to acquire the latter for $850 million.
said the deal would take the form of debt and cash financing and was expected to be completed by the end of the year.
it's also worth noting that the deal also comes with tax breaks, which are adjusted for the present value of the expected tax breaks and actually reduce the purchase price to about $810 million.
, the fifth-largest deal announced so far this year in healthcare technology, despite being worth less than $1 billion.
founded in 1988, Key Surgical is the world's leading supplier of sterile treatment and operating room supplies, providing consumables for hospitals and surgical facilities.
is known to supply thousands of products, mainly medical devices, operating room supplies and surgical supplies, to nearly 10,000 medical facilities in 70 countries.
" Key Surgical's focus on sterile handling, operating room supplies and endoscopy is ideal for our core healthcare customers, and this acquisition complements and expands Styris' product line.
," said Walt Rosebrough, president and chief executive officer of STERIS.
.